T-cell acute lymphocytic leukemia 2 (TAL2)

T-cell acute lymphocytic leukemia 2 (TAL2) is a basic helix-loop-helix (bHLH) transcription factor encoded by the TAL2 gene in humans[1][3][5]. TAL2 is involved in the regulation of gene expression through protein dimerization and DNA binding activities, with a primary biological role in hematopoietic and T-cell lineage development. Chromosomal translocations involving TAL2, particularly t(7;9)(q34;q34.3), lead to aberrant expression and are implicated in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL), although TAL2-associated rearrangements are relatively rare compared to other T-ALL oncogenes[1][3][5]. TAL2 is considered an oncogenic transcription factor, but there are currently no approved drugs that directly target it. Its main significance is as a molecular driver and biomarker in subsets of T-ALL[1][3][5].

Other names

TAL bHLH transcription factor 2T-cell acute lymphoblastic leukemia 2TAL2

therapeutic modulation would theoretically involve inhibition of aberrant transcription factor activity, but no clinically established MoA via small molecules or biologics exists as of now